EOS-215 is a potential best-in-class anti-TREM2 (anti-Triggering Receptor Expressed on Myeloid Cells 2) antibody that we are developing to inhibit the multi-faceted immunosuppressive activity of TREM2. In normal conditions, TREM2 regulates myeloid cells, primarily macrophages, to maintain tissue homeostasis by controlling inflammation and promoting tissue repair. When cancer hijacks TREM2 signaling, it allows for metabolic reprogramming, unregulated efferocytosis, immunosuppression from tumor-associated macrophages (TAMs), tumor growth via angiogenesis, and immune system evasion and survival via fibrotic remodeling in the tumor microenvironment.

We have designed EOS-215 to reverse the creation and reprogram the macrophages in the tumor microenvironment, creating a hospitable environment amenable to a T cell response.